The coming together of Ranbaxy and Daiichi Sankyo is a path-breaking
confluence that, in one sweep, catapults the new, empowered
entity to the status of the world's 15th largest pharmaceutical Company.
Individually, the two pharmaceutical giants are formidable - one, India's
largest generics Company and the other, among the largest innovator
companies in Japan. And now, this synchronisation of proven, individual
competencies in a unified, complementary platform has catalysed a highoctane
thrust into a far-reaching transformational trajectory.
This synergy of tested success mantras energises the combined business model
manifold. It ushers in an expanded global footprint, a wider product portfolio,
added revenue streams and better cost-competitiveness, while allowing both
companies to optimise research & manufacturing capabilities and much more.
|
